At the completion of this activity, the participant will be able to:
1. Recall the patient population studied in major atrial fibrillation and DVT/PE DOAC trials
2. Discuss subgroup analyses and available cohort studies regarding DOAC use in patients with advanced kidney disease
3. Review available subgroup and post-hoc analyses regarding DOAC use in patients with elevated BMI
4. Identify the most appropriate DOAC agents for use in the CKD and obese patient population in practice

Session date: 
11/23/2020 - 12:00pm to 1:00pm EST
Location: 
Zoom: https://zoom.us/j/92097159387
Dial: 301 715 8592 or 312 626 6799
Meeting ID: 920 9715 9387
Passcode: 049657
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance

Please login or register to take this course.